EPOC READER & POWER SUPPLY
Report
- Report Number
- 3002637618-2021-00028
- Event Type
- Malfunction
- Date Received
- April 19, 2021
- Date of Event
- April 1, 2021
- Report Date
- May 19, 2021
- Manufacturer
- EPOCAL INC.
- Product Code
- CGL
- UDI-DI
- 00809708016685
- PMA / PMN Number
- K113726
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- GA, US
- Reporter Occupation
- 501
Narratives
AFTER MULTIPLE REQUESTS FOR INFORMATION BY THE COMPLAINT PREPARER, THE CUSTOMER WAS UNABLE TO PROVIDE THE REQUIRED INFORMATION TO PERFORM AN INVESTIGATION. DCU SHOWED DUE DILIGENCE IN ATTEMPTING TO OBTAIN INFORMATION 5 DIFFERENT TIMES. THE COMPLAINT PREPARER LEFT ADDITIONAL MESSAGES WITHOUT SUCCESS. WITHOUT AN INVESTIGATION, THE ROOT CAUSE CANNOT BE DETERMINED AND THEREFORE THE COMPLAINT CANNOT BE CONFIRMED. SIEMENS RECOMMENDS THAT THE CUSTOMER REVIEW THEIR SAMPLE COLLECTION PROTOCOL AND PRACTICE PROPER SAMPLE HANDLING, AS THIS MAY HAVE A DIRECT IMPACT ON THE HEMATOCRIT. ADDITIONALLY, THE TYPE OF ANTICOAGULANT USED AS WELL AS TESTING DELAYS CAN ALSO IMPACT TEST RESULTS IF NOT PROPERLY CONSIDERED.
THE CUSTOMER STATED THAT REPEAT TESTING WAS PERFORMED TO CONFIRM CORRECT RESULTS. THE CUSTOMER DID NOT PROVIDE THE CARD LOT NUMBER FOR INVESTIGATION. IT HAS BEEN REQUESTED. IF THE CARD LOT IS PROVIDED, THIS ISSUE WILL BE INVESTIGATED BY LOOKING AT IN-HOUSE DATA, FINISHED GOODS TESTING, LIFETIME TESTING, RETAIN TESTING AND A SEARCH TO SEE IF THERE ARE ANY OTHER COMPLAINTS ON THIS SAME CARD LOT. THE CAUSE OF THIS EVENT IS UNKNOWN.
THE CUSTOMER REPORTED A DISCREPANT HIGH HEMATOCRIT RESULT WHEN TESTED FOR A TOTAL OF THREE TIMES ON THE EPOC READER AND COMPARED THE RESULT TO A NON-SIEMENS HEMATOLOGY ANALYZER. THERE WAS NO REPORT OF INJURY DUE TO THIS EVENT.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 584261 | EPOC READER & POWER SUPPLY | EPOC | CGL | EPOCAL INC. | HR-1002-00-00 | 00809708016685 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |